Andexanet versus prothrombin complex concentrates: Differences in reversal of factor Xa inhibitors in in vitro thrombin generation

por Lu, Genmin, Lin, Joyce, Bui, Khanh, Curnutte, John T., Conley, Pamela B.
Publicado 2020

Thirty‐day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life‐threatening direct oral anticoagulant‐related bleeding

por Cohen, Alexander T., Lewis, Megan, Connor, Augusta, Connolly, Stuart J., Yue, Patrick, Curnutte, John, Alikhan, Raza, MacCallum, Peter, Tan, Joachim, Green, Laura
Publicado 2022

Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model

por Lu, Genmin, Pine, Polly, Leeds, Janet M., DeGuzman, Francis, Pratikhya, Pratikhya, Lin, Joyce, Malinowski, John, Hollenbach, Stanley J., Curnutte, John T., Conley, Pamela B.
Publicado 2018

Hemostatic Efficacy and Anti-FXa (Factor Xa) Reversal With Andexanet Alfa in Intracranial Hemorrhage: ANNEXA-4 Substudy

por Demchuk, Andrew M., Yue, Patrick, Zotova, Elena, Nakamya, Juliet, Xu, Lizhen, Milling, Truman J., Ohara, Tomoyuki, Goldstein, Joshua N., Middeldorp, Saskia, Verhamme, Peter, Lopez-Sendon, Jose Luis, Conley, Pamela B., Curnutte, John T., Eikelboom, John W., Crowther, Mark, Connolly, Stuart J.
Publicado 2021